07:50 AM EDT, 09/18/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) , which is developing small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, on Wednesday said the first participant has been dosed in a Phase 1 clinical study of SAT-3247, an oral small molecule drug designed to regenerate skeletal muscle in Duchenne muscular dystrophy (DMD or Duchenne) and other degenerative or injury conditions involving muscle tissue.

"We are excited to announce the dosing of the first participants in our Phase 1 clinical trial of SAT-3247, transforming Satellos into a clinical stage company. This milestone marks a significant step in our commitment to developing innovative therapies to regenerate muscle for those living with Duchenne and other muscle degenerative or injury conditions," said Frank Gleeson, Co-founder and CEO, Satellos.